BioPharmSignal logoBioPharmSignal

Biotech News

GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans

GSK plc (GSK)GSK plcCompany update

Voluntary agreement delivers on all four of President Trump’s requests and reduces the cost of medicines for Americans.

Related news

GSKGSK plc2026-06-12 12:00 EST

GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome

GSKGSK plc2026-06-09 12:00 EST

GSK enters agreement to acquire Nuvalent, Inc.

RVMDRevolution Medicines2026-07-22 20:05 EST

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

INVAInnoviva2026-06-16 12:00 EST

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

TEVATeva Pharmaceutical Industries2026-07-29 11:00 EST

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

TEVATeva Pharmaceutical Industries2026-07-09 12:30 EST

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

View all latest news

GSK plc

Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...

Recent company news

GSKGSK plc2026-07-29 09:08 EST

Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

GSKGSK plc2026-07-28 12:05 EST

GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK

GSKGSK plc2026-07-28 12:00 EST

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

GSKGSK plc2026-07-28 11:00 EST

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

GSKGSK plc2026-07-27 14:55 EST

ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV

Stock data

Close
52.17 USD
Market cap
98.26B USD
Exchange
NYSE
Sector
Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
Location
United States